FDA Approves Novo Nordisk Obesity DrugTuesday, December 30, 2014
The U.S. Food and Drug Administration (FDA) recently approved Saxenda, an injectable drug developed by Novo Nordisk. Although Saxenda is a formulation of the type 2 diabetes drug, liraglutide, also known as Victoza, Saxenda has been indicated for the treatment of weight management only. Saxenda is not for the treatment of type 2, but is looking to lend a hand to the worldwide obesity problem.
The drug withstood three clinical trials that consisted upwards of 4,800 overweight patients. However, it’s still understood that this should be taken as part of healthier lifestyle modifications and not be the driving force in a person’s weight loss.
“Saxenda, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides an additional treatment option for chronic weight management for people who are obese or are overweight and have at least one weight-related comorbid condition,” says James Smith, MD, MS, acting deputy director of the Division of Metabolism and Endocrinology Products in FDA’s Center for Drug Evaluation and Research.
Source: Food and Drug Administration